Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). Options to purchase 157,850 shares were granted to five employees effective June 25, 2026, and options to purchase 22,500 shares were granted to one employee effective June 29, 2026.
